@article{23d5b5f51f5341258a4c38e827c4ed1d,
title = "US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency",
abstract = "Background: The treatment of hereditary angioedema (HAE) has undergone dramatic changes as newer medicines have become available in recent years. Optimal care of these patients requires a comprehensive management plan. Although several consensus papers have been published concerning the diagnosis and treatment of HAE, guidelines for a comprehensive management plan have not been developed. Objective: To develop state-of-the-art recommendations for the treatment and management of HAE due to C1 inhibitor (C1INH) deficiency in the United States. Methods: Members of the US Hereditary Angioedema Association Medical Advisory Board began by reviewing the literature concerning treatment of HAE. Preliminary recommendations were developed based on the literature review, discussions in a face-to-face meeting, and refinements in a series of drafts. Final recommendations reflect the unanimous consensus of the medical advisory board and the US Hereditary Angioedema Association leadership. Results: Recommendations are provided regarding a comprehensive care plan for HAE, including the following: development of an overall management plan, treatment of angioedema attacks, prophylactic treatment, and patient monitoring. Conclusion: A comprehensive individualized management plan developed between an expert HAE physician and the patient, in collaboration with local medical providers and emergency departments, can provide patients with the best opportunity to lead a normal life.",
keywords = "Bradykinin, C1 inhibitor, Hereditary angioedema, Management, On-demand treatment, Prophylactic treatment",
author = "Zuraw, {Bruce L.} and Aleena Banerji and Bernstein, {Jonathan A.} and Busse, {Paula J.} and Christiansen, {Sandra C.} and Mark Davis-Lorton and Frank, {Michael M.} and Li, {Henry H.} and Lumry, {William R.} and Marc Riedl",
note = "Funding Information: Conflicts of interest: B. L. Zuraw has received travel support from the US Hereditary Angioedema Association; is a member of adjudication boards for Sanofi-Aventis, Novartis, and Genentech; has consultant arrangements with Dyax, Isis, BioCryst, and CSL Behring; has received grants from Shire ; has received payment for lectures from Dyax; and has received travel support from ViroPharma. A. Banerji has received grants from Shire , ViroPharma , and Dyax; has consultant arrangements with Shire, CSL, and Dyax; has received fees for participation in review activities from Shire; and has received payment for development of educational presentations from Medscape . J. A. Bernstein is a member of the board of directors for the American Academy of Allergy, Asthma, and Immunology; is a board member for Allergists for Israel; is on the medical advisory boards for the Hereditary Angioedema Association and Mastocytosis; has consultant arrangements with Dyax, Shire, CSL Behring, and ViroPharma; is employed by the Bernstein Allergy Group and Bernstein Clinical Research; has received grants from Boehringer Ingelheim , Forest , ViroPharma , CSL Behring, Dyax, Shire, Pharming, and Novartis; has received payment for lectures from Shire, Teva, Dyax, ViroPharma, and CSL Behring; has received payment for the development of educational presentations from ViroPharma, Shire, and Medscape; and is editor-in-chief of the Journal of Asthma. P. J. Busse has consultant arrangements with ViroPharma, Dyax, CSL Behring, and Shire; has received grants from CSL Behring ; has a pending grant with ViroPharma; and has received payment for development of educational presentations from the Robert Michael Educational Institute . S. C. Christiansen has received travel support from the US Hereditary Angioedema Association. M. Davis-Lorton has received payment for lectures from Dyax and ViroPharma. M. M. Frank is on a committee that is developing a quality-of-life questionnaire and speaks about the disease without medication bias supported by an educational institute. H. H. Li has consultant arrangements with Dyax and CSL Behring; has received speakers fees from Dyax, CSL Behring, and ViroPharma; and has received research support from Dyax and ViroPharma. W. R. Lumry has received travel support from the Hereditary Angioedema Association Medical Advisory Board; has consultant arrangements with ViroPharma, Dyax, CSL Behring, Shire HGT, and BioCryst; has received grants from ViroPharma, CSL Behring, Dyax, Shire HGT, and Pharming; has received payment for lectures from ViroPharma, CSL Behring, Dyax, and Shire HGT; and has received payment for development of educational presentations from ViroPharma and Shire HGT. M. Reidl has consultant arrangements with ViroPharma, CSL Behring, Dyax, Shire, Isis, and BioCryst; has received grants from ViroPharma, CSL Behring, Dyax, Shire, and Pharming; and has received payment for lectures from ViroPharma, CSL Behring, Dyax, and Shire. ",
year = "2013",
month = sep,
doi = "10.1016/j.jaip.2013.07.002",
language = "English",
volume = "1",
pages = "458--467",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "5",
}